Hemoject IV Injection Injection

About Hemoject IV Injection 500 mg/10 ml

Hemoject IV Injection is a parenteral iron preparation containing the generic ferric carboxymaltose. It is given by a healthcare professional to treat iron deficiency anemia in certain adults, and it delivers iron directly into the body through a vein.

There are 15 brands of Ferric Carboxymaltose listed in Bangladesh. By unit price, Hemoject IV Injection is among the cheapest of them. The lowest listed price is Ferium Injection 500 mg/10 ml at ৳ 700 per unit.

What is Hemoject IV Injection 500 mg/10 ml?

Hemoject IV Injection, strength 500 mg/10 ml, is made by Nuvista Pharma Ltd. It belongs to the parenteral iron preparations, meaning iron is given into a vein rather than by mouth. Ferric carboxymaltose carries iron in a complex that the body's cells take up and use to help rebuild iron stores. It is intended for adults with iron deficiency anemia who cannot tolerate oral iron, do not respond well to it, or who have non-dialysis dependent chronic kidney disease. Because it is an injection, it is given under medical supervision. The dose and course are decided by the doctor.

Uses of Hemoject IV Injection

Hemoject IV Injection is used to treat iron deficiency anemia in adults who have intolerance to oral iron or an unsatisfactory response to oral iron, and in adults with non-dialysis dependent chronic kidney disease. Iron is needed to make hemoglobin, which carries oxygen around the body. The doctor confirms that iron deficiency is the cause of the anemia before this injection is used.

How to use Hemoject IV Injection

Hemoject IV Injection is given by a healthcare professional into a vein; it is not for self-administration at home. The doctor decides the dose and course based on your body weight, your iron needs and your response. Staff watch you during and after the injection for any reaction. Tell the person giving it straight away if you feel unwell, dizzy, itchy or short of breath. Ask your doctor or pharmacist about anything you are unsure of.

Side effects of Hemoject IV Injection

Some people feel sick or vomit, have a headache, dizziness, flushing, or a change in blood pressure after receiving this injection. Itching, rash, hives, wheezing, a metallic taste, constipation, and discoloration at the injection site have also been reported. Serious allergic-type reactions can occur, which is why it is given where such reactions can be managed. Tell the healthcare staff promptly about any unusual symptoms.

Safety and precautions

Hemoject IV Injection is given only under medical supervision, and staff watch for allergic-type reactions during and after it. It should not be used by anyone with hypersensitivity to any of its components. In pregnancy it falls under a category where animal studies showed harm to the fetus and human data are limited, so the doctor weighs benefits and risks. Whether it is safe while breastfeeding should be discussed with the doctor. Tell your doctor about other conditions and medicines before receiving it.

Frequently asked questions

Is Hemoject IV Injection safe in pregnancy or breastfeeding?

In pregnancy it is in a category where animal studies showed harm to the fetus and human data are limited, so the doctor weighs benefits and risks. Safety during breastfeeding should be discussed with your doctor. Do not decide on your own; ask the doctor managing your care.

What is Hemoject IV Injection used for and what kind of medicine is it?

It is a parenteral iron preparation containing ferric carboxymaltose, given into a vein. It is used for iron deficiency anemia in adults who cannot tolerate or do not respond well to oral iron, or who have non-dialysis dependent chronic kidney disease.

Who should avoid it or ask the doctor first?

Anyone with hypersensitivity to any of its components should not receive it. People who are pregnant or breastfeeding, or who have other medical conditions or take other medicines, should speak to the doctor first. The doctor decides whether it is suitable for you.

How is Hemoject IV Injection given?

It is given by a healthcare professional into a vein, not by self-injection at home. The doctor decides the dose and course based on your weight, iron needs and response, and staff watch you during and after the injection for any reaction.

Indications

Ferric Carboxymaltose is indicated for the treatment of iron deficiency anemia in adult patients-
  • Who have intolerance to oral iron or have had unsatisfactory response to oral iron
  • Who have non-dialysis dependent chronic kidney disease.

Pharmacology

Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.

Dosage & Administration

For patients weighing 50 kg or more: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.

For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.

The dosage of Ferric Carboxymaltose is expressed in mg of elemental iron. Each mL of Ferric Carboxymaltose contains 50 mg of elemental iron. Ferric Carboxymaltose treatment may be repeated if iron deficiency anemia reoccurs.

Administer Ferric Carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.

When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferric Carboxymaltose solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.

Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferric Carboxymaltose is intended for single use only. Any unused drug remaining after injection must be discarded.

Avoid extravasation of Ferric Carboxymaltose since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferric Carboxymaltose administration at that site.

Interaction

There are no known drug interactions and none well documented.

Contraindications

Hypersensitivity to any of its components.

Side Effects

Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions

Pregnancy & Lactation

Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Precautions & Warnings

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.

Hypertension: 
Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.

Storage Conditions

Do not store above 30°C. Do not freeze.

Alternative brands of Ferric Carboxymaltose

Other brands with the same generic name, cheapest first.

See all 15 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.